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ABSTRACT 
Background: Previous work in the laboratory has demonstrated that a novel cell 
population of CD34 negative non-hematopoietic umbilical cord blood stem cells (nh-
UCBCs) can be isolated from the human umbilical cord blood (UCB). These cells when 
intravenously delivered into a transient or permanent middle cerebral artery occlusion 
(MCAO) rat model of stroke, 2 days after injury, helped alleviate the stroke induced 
behavioral deficits and reduced the infarct size. In addition, injection of nh-UCBCs 
directly into the brain near the site of ischemic injury also ameliorated limb placement 
deficits.   
Purpose: The central goal of this project was to explore the mechanism(s) by which  
CD34 negative nh-UCBCs help ameliorate the neurological deficits when injected 
systemically into a rat model 48hrs after inducing stroke (acute period), and when 
directly injected into the brain at 3 months after ischemic injury (chronic period). The 
improvement in behavior of the rat model was evaluated based on the neurological 
severity score (NSS) derived from performing various functional tests. The first aim of 
the project was to check whether the nh-UCBCs has an elevated level of anti-
inflammatory cytokines which helps in reducing the inflammation that results from stroke 
and thus helps in the behavioral improvement of the animal model during the acute 
period after an ischemic stroke. In order to test this aim, the cytokine levels in the nh-
UCBCs and nh-UCBS cell conditioned media were tested using qRT-PCR and cytokine 
protein array, respectively.  The next aim was to check whether the nh-UCBCs that are 
injected intravenously into the rat model can modulate the phenotype of immune cells in 
the brain. To test this aim we analyzed the expression of various M1 and M2 
macrophage/microglia markers in the BV2 cells (murine microglial cell line) cultured in 
different conditions by qRT-PCR. We expect to see a shift from M1 type 
macrophages/microglia phenotype to M2 type macrophage/microglia phenotype which is 
responsible for eliminating inflammation and help in wound healing.  
During the chronic period after a stroke, the inflammatory environment has most likely 
subsided, and the restorative effects of injecting nh-UCBCs directly into the brain 
parenchyma is most likely not due to the modulation of the inflammatory environment.  
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We postulate that it might be due to the induction of fiber sprouting by neurons from the 
non-damaged hemisphere towards the site of injury. In order to test this trophic action of 
the neurons and the sprouting of fibers in the presence of the non-hematopoietic 
population of human umbilical cord blood, an in vitro tissue culture model is used. The 
plausible mechanism in this model is that the nh-UCBCs can induce neural plasticity and 
therefore enhance the connectivity between the interhemispheric neuronal connections. 
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INTRODUCTION 
Stroke is the fourth leading cause of death in the United States; approximately 795000 
people have a new or recurrent stroke each year 
[1]
. 85% of strokes are caused by a 
blockage of a blood vessel in the brain and are called ischemic strokes. It is one of the 
most economically and emotionally devastating diseases 
[2]
.
 
The incidence of stroke is 
expected to dramatically rise as the population ages, as stroke risk increases with age 
[1]
. 
              Stroke occurs when the blood flow to the brain stops due to a blockage formed 
by a clot. Due to this, the brain cells are deprived of the necessary oxygen and nutrients 
and hence are prone to cell death. Approximately 1.9 million neurons die every minute 
and though some brain cells are viable, they are dysfunctional due to the low flow state 
during ischemic stroke 
[3]
.
 
Intravenously administered Ateplase (recombinant tissue 
plasminogen activator [rt-PA]) is the only Food and Drug administration approved 
pharmacologic treatment for acute cerebral infarction in the United States. Administering 
rt-PA within 3 hours of symptoms results in a decrease in mortality as it is a thrombolytic 
agent that restores the cerebral blood flow by dissolving the clot in the brain 
[4]
. But due 
to the lack of awareness of the common symptoms of stroke, a majority of the ischemic 
stroke patients are unable to access the acute therapy. Beyond the 3- 4.5 hours’ time 
window, the three acceptable methods of treatment for the acute ischemic stroke are 
intra-arterial (IA) administration of t-PA (up to 6 hours), use of MERCI retrieval device 
(up to 8 hours)
[5]
 and penumbra aspiration system (up to 8 hours) 
[44]
 for revascularization 
of the vessel occlusion in patients. But the efficacy of using these mechanical devices for 
clot removal has never been proven to be superior to rt-PA. Moreover there is no 
effective therapy that is available for chronic stroke. Hence developing new therapeutic 
strategies is critical for stroke treatment. 
              Stem cell based approaches are novel therapies for stroke that have expanded 
substantially over the past decade. The animal experimentation data obtained from 
treatment with stroke are promising and several clinical trials are currently being carried 
out. Studies focusing on the optimal dose and the route of administration of the stem cells 
are also being investigated 
[6][51]
. Factors such as mode of action, immunogenicity, 
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harvesting, proliferative capacity, tumorigenicity and the overall feasibility of use of 
these stem cells should also be considered before the use of the stem cells for stroke 
treatment 
[7]
. 
The nature of stroke and the mode of action of the stem cells are both diverse. Hence 
special consideration is to be given for the use of stem cell derivatives that are used to 
treat stroke conditions 
[7]
. The possible sources of stem cells for stroke therapy are neural 
stem cells from human fetal brain, pluripotent cells generated from blastocysts (ES cells) 
or from somatic cells [induced pluripotent stem cells (iPS cells)] that are capable of being 
expanded and differentiated into specific cell types 
[6]
. Moreover, recent studies have also 
shown the generation of specific types of neurons by direct conversion of fibroblasts (iN 
cells) for use in stroke therapy 
[56]
. The adult stem cells like bone marrow-derived stem 
cells such as hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), 
endothelial progenitor cells (EPCs), very small embryonic like stem cells (VSELs) and 
neural stem cells (NSCs) are also being investigated as a possible stem cell based 
approach for stroke recovery. Transplantation of umbilical cord blood derived and bone 
marrow derived hematopoietic stem cells into animal models of stroke also have 
demonstrated functional recovery, reduced infarct size and higher expression of 
neuroprotective  factors, such as BDNF and VEGF 
[6] [7]
. 
1. Human umbilical cord blood stem cells 
Human umbilical cord blood stem cells are primitive adult stem cells and have the ability 
to repopulate the different blood lineages 
[8] [9] [10]
.
 
It is a mononuclear fraction, which 
includes many cell types like hematopoietic progenitors, lymphocytes, monocytes and 
mesenchymal stromal cells and is a desirable potential source for transplantation
[11] [12]
. 
Due to their heterogenic nature, these stem cells are considered to be immunologically 
immature and earlier studies with human UCBS cells have shown that these cells have an 
influence in modulating the immune response and reduce the level of pro-inflammatory 
cytokines in response to the inflammation which results from stroke 
[8]
. Moreover in 
comparison to bone marrow transplantation, transplantation of cord blood into an 
allogeneic recipient does not require a perfect human leukocyte antigen (HLA) matched 
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donor 
[57]
. The chances of acute and chronic graft versus host diseases (GVHDs) is also 
lesser in UCB transplantation compared to bone marrow transplantation
 [13] [14]
. 
1.1 CD34 negative non-hematopoietic umbilical cord blood stem cells 
(nh-UCBCs) 
Flow cytometry, clonogenic assays and the expression of CD antigens coupled with self-
renewal proliferation assays are used in order to distinguish between the hematopoietic 
stem, progenitor cells and other components of the cord blood 
[58]
. CD34 is a type 1 
transmembrane glycoprotein that is used as a phenotypic marker capable of recognizing 
the cell surface components in a heterogeneous substrate such as cord blood in order to 
identify and sort the different cell types present 
[45]
. Previous work in the laboratory has 
demonstrated that a novel cell population of CD34 negative non-hematopoietic umbilical 
cord blood stem cells (nh-UCBCs) can be isolated from the human UCB by culturing the 
mononuclear fraction and cell sorting for the specific CD antigen. These nh-UCBCs that 
were isolated from the human UCB, exhibited properties of self-renewal and expressed 
high levels of pluripotency markers like OCT-4, REX-1, SOX-2 and NANOG that are 
typically expressed in stem cells 
[15]
. In addition, these cells also expressed specific 
surface markers like SSEA-3, SSEA-4 and tumor rejection antigens like TRA1-60 and 
TRA1-80 that are usually used to characterize human embryonic stem cell lines 
[16] [17] [18] 
[19]
.   
     Moreover, the CD34 negative nh-UCBCs when intravenously delivered into a rat of 
transient or permanent middle cerebral artery occlusion model (MCAO) of stroke at two 
days after injury, helped alleviate the stroke induced behavioral deficits and reduced the 
infarct size 
[15]
. In addition, injection of these cells directly into the brain near the site of 
ischemic injury also ameliorated limb placement deficits.  The mechanism(s) of action, 
however, are yet to be determined.  
     The focus of the thesis was therefore to explore the mechanism(s) as to how the CD34 
negative nh-UCBCs help in ameliorating the neurological deficits when injected 
systemically into a rat model 48hrs after induced with stroke (acute period), and when 
directly injected into the brain at 3 months after the ischemic injury (chronic period).  
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2. Mechanism of action for the recovery process in stroke by using stem 
cell based approach 
The theories for the mechanism of action by which the use of a non-neuronal stem cell 
based approach helps in improving the functional behavior of an animal model induced 
with stroke is based on strategies other than cell replacement 
[6]
. The main effects that are 
possible in mediating the restorative effects in the stroke induced animal model are 
“neuroprotection” which helps in preventing the damaged neurons from undergoing cell 
death within the ischemic penumbra in the acute phase of cerebral ischemia and 
“neurorepair” process in which the broken neuronal networks are repaired in the chronic 
phase of cerebral ischemia. The other mechanisms that can be involved are the 
modulation of the inflammation which occurs after stroke and the promotion of 
angiogenesis.  
               The mechanism of action by which the CD34 negative nh-UCBCs helps in 
improving the behavioral deficits in the animal model of stroke as shown in the previous 
study in the laboratory 
[15]
 could be due to one of the mechanisms above mentioned or a 
combination of  the two mechanisms. 
 
2.1SPECIFIC AIM 1: CD34 negative nh-UCBCs express elevated levels 
of anti-inflammatory cytokines. 
Stroke induced by middle cerebral artery occlusion (MCAO) which leads to the loss of 
oxygen and glucose to the cerebral tissue results in post- ischemic inflammation (figure 
1).  This henceforth triggers the pathological ischemic cascade which causes neuronal 
injury in the ischemic core within minutes after the arterial occlusion 
[20]
.  Earlier studies 
have shown that, cells of the ischemic penumbra region of the brain do not completely 
die due to the damage caused by the ischemic injury and hence this offers a promise that 
if proper therapies are devised, the brain tissue can be rescued and can help reduce post 
stroke disability 
[21]
. 
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Figure 1: Ischemic cascade of events leading to cerebral damage post injury 
[21]
. Ischemic 
stroke causes cell death of the neurons in the region of the brain affected due to the loss of blood 
supply which causes the region to be deficient of glucose and other nutrients. This hence forth 
triggers a series of events like excitotoxicity, oxidative stress, microvascular injury, blood-brain 
barrier dysfunction and post-ischemic inflammation ultimately leading to cerebral damage. 
 
                    The immune response and inflammation are important events that occur as a 
result of stroke 
[21]
. Reducing the inflammatory response by the administration of an anti-
inflammatory agent is a possible mechanism for stroke recovery as it reduces the severity 
of post-ischemic injury. Cytokines are a group of glycoproteins that act as mediators and 
are produced in response to an antigen that help in the regulation of the innate and 
adaptive immune systems. In the brain, cytokines are expressed by both by the cells of 
the immune system and the resident brain cells like neurons and glial cells 
[22]
. 
Peripherally derived cells like the mononuclear phagocytes, T lymphocytes, NK cells and 
polymorphonuclear leukocytes are also known to secrete cytokines that are involved in 
brain inflammation 
[23] 
and thereby potentiating the neurotoxicity within the CNS. It has 
been shown in earlier studies, that the ischemic damage can be decreased in animal 
models by blocking leukocyte adhesion to the endothelia with antibodies to ICAM-1 
[24]
. 
Alternatively, the ischemia induced inflammation can be controlled by modulating the 
pro-inflammatory cytokine level produced in the CNS 
[25] [26]
.   
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               The most studied cytokines related to inflammation in acute ischemic stroke 
includes tumor necrosis factor-α (TNF-α), the interleukins (IL), IL-6, IL-10, IL-20, IL-
1β, IL-2, IL-4 etc. and transforming growth factor (TGF)-β. While IL-1β and TNF-α are 
the important pro-inflammatory cytokines which are responsible for exacerbating the 
cerebral injury and inflammation after the induction of stroke (figure 2),  the cytokines 
like TGF-β and IL-10 are known as the anti-inflammatory cytokines which may be 
neuroprotective 
[27] [28]
.  Research in the past to study the mechanism of human UCB 
treatment in mediating the recovery of rat model of stroke showed that the intravenous 
delivery of human UCB decreased the pro-inflammatory cytokines such as TNF-α, IL-1β, 
and IFN-γ and increased the production of anti-inflammatory cytokines like IL-10 and 
TGF-β in the brain of the stroke induced animal. The up-regulation of the anti-
inflammatory cytokines and the simultaneous down-regulation of the pro-inflammatory 
cytokines helps in reducing the T-cell proliferation that results in a stroke induced animal. 
The human UCB treatment reduced the presence of both activated microglia and 
astrocytes in the brain 
[29]
. Moreover the growth factors such as FGF, EPO and G-CSF 
help in promoting functional recovery and earlier studies show that administering such 
growth factors into an animal model  24 hours after stroke for 7 days enhances the motor 
skill of the animal model  
[16] [17] [18]
. There is increasing evidence that the intravenous 
transplantation of CD34 positive HUCB cells transfected with the glial cell line- derived 
neurotropic factor (GDNF) gene exerts therapeutic benefits in a stroke induced by 
MCAO in rats
 [30]
. The GDNF modified CD34+ cells transplantation into the stroke 
affected animals, showed significant increase in the GDNF protein production levels in 
the infarcted hemisphere of the brain, which in turn is responsible for reducing the brain 
infarction volume helping in the functional recovery of the stroke induced animal model 
[30]
. In some cases, certain cytokines might act either as pro- inflammatory cytokines or as 
anti-inflammatory cytokines depending on the environment. For example, certain 
cytokines that are believed to be pro-inflammatory agents responsible for inflammation 
that results after stroke like IL-8, MCP-1 and IL-1β have been implicated to be the first 
line of defense in the inflammatory reaction. They are produced more extensively in the 
brain compared to other chemokine’s in the brain.  On the other hand, certain 
chemokine’s like MCP-1 and macrophage inflammatory protein (MIP) -1 α are seen to be 
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elevated in the ischemic brain as observed in an in-vivo study 
[31] 
and are believed to play 
an important role in the infiltration of monocytes into the CNS under pathological 
conditions 
[32]
. 
Hence in the first part of our study we hypothesize that the nh-UCBS cells that are 
injected intravenously into the stroke model, induce recovery by secreting anti-
inflammatory cytokines that decrease the inflammation in the brain and thereby help 
enhance neuroprotection. For this we examine the gene expression for the various pro-
inflammatory and anti-inflammatory cytokines in the nh-UCBCs and the protein 
expression for the cytokines in the nh-UCBS cell conditioned media. 
 
Figure 2: The early vascular, perivascular and parenchymal events triggered by stroke and 
reperfusion 
[21]
.  Ischemic stroke leads to blood clotting and hence causes the release of pro-
inflammatory cytokines like IL-1α. The MMP activation leads to blood brain barrier (BBB) 
breakdown and matrix proteolysis which contributes to BBB leakiness. The release of cytokines 
like TNF and IL-1β from the mast cells and perivascular macrophages guides leukocyte migration 
across the vessel wall. 
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2.2 SPECIFIC AIM 2: nh-UCBCs are responsible for activating the 
immune cells from in brain, and other immune/peripheral organs of the 
body that help in decreasing the inflammation and participate in tissue 
remodeling after injury. 
Microglial cells are resident immunocompetant macrophages of the brain
 [21]
. These 
immune cells in the brain can provide immunosurveilllance but can also be toxic 
[33]
 
(figure 3a, 3b). Research in the past has shown that in a stroke model, the depletion of the 
proliferative microglia exacerbates the injury 
[34]
 and the injection of microglia into the 
ischemic brain helps in ameliorating the injury 
[35]
. Hence after the induction of ischemic 
stroke, the microglial cells that are activated can transform into phagocytes which can 
release many cytotoxic and/or cytoprotective substances 
[21]
. 
a) 
 
 
 
 
 
 
b) 
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Figure 3: The cytotoxic and cytoprotective role of the microglia in the brain 
[21]
. a) Cytotoxic 
effect: Microglial cells contribute to post-ischemic inflammation by the production of TNF, IL-
1β, potential cytotoxic molecules including NO, ROS, prostanoids and other proinflammatory 
cytokines b) Cytoprotective effect: Microglial cells contributing to the resolution of 
inflammation and tissue repair by the production of cytokines IL-10, TGF-β and several growth 
factors including IGF. 
               
              In order to study the role of microglia in neuroprotection, a large number of 
animal models would be required. In our study it was observed that the isolation of the 
inflammatory cells from bone marrow of the rat resulted in low yield of macrophages 
which limited further analyses. Hence in order to study the immune cells and their 
contribution to the effect of neurprotection post nh-UCBS cell treatment, we used BV2 
cell line which is an immortalized murine microglial cell line that is used as a substitute 
for primary microglia 
[59]
. Using this cell line has advantages compared to primary 
culturing of the microglial cells from the rat brain tissue affected with stroke, as it 
reduces the necessity of continuous cell preparations and animal experimentation. A 
major impediment with primary culturing is that microglial cells are difficult to isolate in 
large numbers. This cell line also reproduces the in-vivo situation of the primary 
microglial cells with high fidelity 
[36]
. Their response to lipopolysaccharide (LPS) is 
comparable to the response of the microglial cells which get activated after ischemia in- 
vivo.  
               Peripheral microglial cells show two distinct activation patterns otherwise 
known as the microglial subsets i.e. the classically activated pro-inflammatory M1 
Phenotype (induced by  IFN and LPS) and the alternatively activated M2 cells (induced 
by IL-4 or IL13) activation 
[37]
.  The high M1/M2 macrophage ratio has significant 
implications for CNS repair 
[38]
. M2 phenotypical cells help in decreasing the 
inflammation caused due to stroke and also facilitate wound healing by recruiting 
scavenger receptors and matrix degrading enzymes that enhance phagocytosis thus 
helping in the tissue remodeling process 
[39]
. The immune cell (Microglia and/or 
infiltrating macrophages) mediates the repair process by orchestrating signal cross talk 
between the injured site and the macrophages/microglial cells that are activated (figure 
3b). The site of injury produces signals like UTP and ATP that attract microglia and 
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macrophages through P2Y2 receptors. The UDP signal released by the phagocytic cells 
acts on the P2Y6 receptors which stimulates the microglial phagocytosis and hence 
phosphatidylserine (PtdSer) protein is translocated to the outermost layer of the plasma 
membrane of apoptotic cells.  T-cell immunoglobulin, TIMP-4 and EGF-8 which are the 
PtdSer binding proteins present on the surface of the immune cells are involved in the 
clearance of dead cells. The immune cells like the macrophages and microglial cells 
when activated; phagocytize by engaging Fc receptors on the phagocytic cells. This 
action of Phagocytosis promotes the secretion of the anti-inflammatory cytokines like IL-
10, TGF-β which in-turn is responsible for the suppression of the antigen presenting cells, 
promotes T- reg cells formation, inhibits the expression of adhesion molecules in 
endothelial cells and reduces the secretion of the pro-inflammatory cytokines 
[40]
. 
Previous studies of human UCB treatment for stroke, demonstrated that the cell survival 
was increased and the release of nitric oxide by the resident microglia (an innate 
inflammatory response) was seen to be reduced back to normal levels following the 
incubation with the HUCB cells 
[41] [42]
. It was also shown that the HUCB cell 
transplantation into a stroke model impaired the secretion of IL-1β by microglial cells in 
the brain. Moreover the viability of the microglia was also decreased following the 
treatment 
[43]
. 
             A previous study in the lab demonstrated that when CD34 negative nh-UCBCs 
were administered intravenously, these cells were not entirely present in the brain. Hence 
we hypothesize that the cells injected are being carried by the blood to the brain and other 
peripheral/immune organs like the spleen, bone marrow and lymph nodes in the body 
from where these organs are responsible for the activation the immune cells which 
secrete the necessary anti-inflammatory cytokines in response to the inflammation that 
results when stroke is induced. We believe that the microglial cells when activated in a 
stroke model undergo transition from M1 phenotype to M2 phenotype in the presence of 
the nh-UCBCs thus down regulating inflammation and facilitating the wound healing 
process. Hence, we expect to see higher expression of M2 phenotype markers compared 
to M1 phenotype markers in the microglial cells that are activated and co-cultured with 
the nh-UCBS cell conditioned media  
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2.3SPECIFIC AIM 3: nh-UCBCs injected into the brain parenchyma 
are responsible for the trophic action of endogenous neurons/ sprouting 
of nerve fiber from the unaffected area of the brain to the site of injury 
thus helping in the tissue repair process. 
The other possible mechanism of recovery after stroke using a stem cell based approach 
is neuroplasticity 
[7]
. Neuroplasticity refers to the organizational changes in the brain that 
help the individual endogenous neurons or neuronal networks to adapt to their function. 
Stem cells can help in the augmentation of this process of neuroplasticity by recruiting 
various mechanisms of recovery including sprouting and unmasking 
[7]
. There is 
increasing evidence that the axonal sprouting and rewiring in the adult central nervous 
system contributes to the functional plasticity and behavioral recovery after ischemic 
stroke 
[54]
.  The treatment with bone marrow MSCs into an animal model of stroke 
demonstrated the axonal plasticity of long distance inter- and intra-cortical connections 
between the primary motor and pre motor areas of the brain facilitating the recovery of 
the brain from stroke 
[55]
. 
              The concept of sprouting of the endogenous nerve fibers has been observed 
previously in our lab when CD34 negative nh-UBSCs where injected directly into the 
brain parenchyma of a rat model induced with stroke. This led to a 50% reduction in the 
lesion volume compared to the saline treated controls 
[15]
. Four weeks after grafting, by 
anterograde tracer experiments using biotinylated dextran amines (BDA) injected at the 
site of the injury, it was demonstrated that the grafted nh-UBSCs in the collateral side of 
the brain, facilitated the sprouting of nerve fibers towards the site of injury. In the chronic 
period after a stroke; the inflammatory environment is mostly subsided, and the 
restorative effects of injecting nh-UCBSCs directly into the brain parenchyma is most 
likely not due to the modulation of the inflammatory environment.  Hence we postulate 
that it might be due to the induction of fiber sprouting by neurons from the non-damaged 
hemisphere towards the site of injury. In order to test this trophic action of the neurons 
and the sprouting of fibers in the presence of the non-hematopoietic population of human 
umbilical cord blood, an in-vitro tissue culture model is used in our study. The hypothesis 
here is that the nh-UCBCs help increase the axonal and dendritic lengths, and the number 
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of branch points in the neurons compared to the neurons cultured in the other culture 
conditions. 
Previous Studies in the Lab 
Isolation and phenotype analysis of nh-UCBCs from Human umbilical cord blood 
stem cells 
It was shown that isolation of a novel population of stem cells known as the CD34 
negative UCBCs was possible from human umbilical cord blood 
[15]
. After 7 days in 
culture, these cells doubled in number and at 14 days, attached to the surface of the 
fibronectin coated tissue culture plate. These CD34 negative nh-UCBCs were seen to be 
elongated and also formed spindle like cells. Expression of the stem cell transcription 
factors like Oct4, Rex-1 and Sox-2 in the nh-UCBCs were confirmed by RT-PCR. In 
order to confirm that they are non-hematopoietic in nature, the cell surface antigens on 
the nh-UCBCs were studied by flow cytometry. It was seen that the cells were negative 
for the hematopoietic markers like CD34, CD45 and MHC class II antigens but showed 
high level of CD13 and CD44, and a moderate level of CD90, CD49, CD10, and  MHC 
Class I antigens. 
Systemic Administration of nh-UCBSCs in Acute Stroke Reduces Infarct Volume 
and Enhances Neurological Function 
In the acute stroke model, where the nh-UCBSCs or saline was administered 48 hours 
after the induction of injury by MCAO, no significant differences were observed based 
on the modified neurological severity score (mNSS) and stepping up test between the 
experimental groups at day 2 and day 7 after the ischemic injury. NSS test and stepping 
up test at Day 14 and Day 28 showed a gradual increase in the NSS and improved 
performance in the stepping up test in the animals which received nh-UCBSCs which 
confirms their progressive recovery over time from 1day to 28 days after MCAO. The 
NSS score of nh-UCBCs injected rat was significantly different from that of the saline 
control animals at Day 14 and 28. 
              Moreover systemic administration of nh-UCBCs into ischemic rat model also 
significantly reduced the infarct volume by 50% (figures 4 and 5). 
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Figure 4: Systemic nh-UCBSC administration in ischemic rats reduces infarct 
volume.   
Left panel – cross sections of brain showing areas of damage in untreated rats.   
Right panel – cross sections of brain showing areas of damage in high passage nh-
UCBSC treated rats (From L. Stone). 
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Figure 5:  Quantification of ischemia-induced brain infarct volume. Shows the 
quantification of the infarct volume in the brain of the saline (Red) treated rats, and rats 
treated with low passage (Blue) and high passage (Green) nh-UCBSCs (From L. Stone). 
 
Localized Intraparenchymal Transplants of nh-UCBS cells: Improves Neurological 
Function and Enhances Cortico-Cortical Neuronal Connectivity. 
In the chronic stroke model, the nh-UCBSCs or saline was administered into Sprague 
Dawley or SHR rats 3 months after the induction of injury by MCAO. The NSS was used 
in order to track the change in the behavior of these animal models at day 2, week 1, 
week 2, week 4 and week 8 after treatment. It was observed that after the induction of 
stroke, there was no significant difference in the NSS score between the group of animals 
treated with nh-UCBSCs and the control groups prior to treatment (figure 6: pre-
transplant). However, a significant increase in the NSS score of the animals treated with 
nh-UCBSCs in comparison to the control groups was observed from week 2 post-
treatment (figure 6: post-transplant). 
In addition after direct injection of the nh-UCBCs into the brain parenchyma, it was 
observed that the host neurons from the contralateral side (unaffected site) of the brain 
were sprouting to the site of injury. This sprouting of the nerve fibers in the brains was 
traced using retrograde tracing technique (figure 7: Left panel). Further greater numbers 
of labeled neurons were seen in the ischemic cortex of the brain (figure 7: Right panel). 
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Figure 6: nh-UCBSC treatment improves neurological severity score (NSS) in rats with chronic 
ischemic brain injury (From C. Nan) 
 
Figure 7: Intraparenchymal transplants of nh-UCBS enhance cortico-cortical neuronal 
connectivity in chronic stroke.  Left panel - retrograde labeling of neuron in ischemic cortex 
following saline injections.  Right panel – retrograde labeling of neurons in ischemic cortex 
following nh-UCBSC transplants. Note increase in the number of labeled neurons in the ischemic 
cortex following nh-UCBSC transplantation (From C. Nan). 
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MATERIALS AND METHODS 
Isolation of a novel nh- CD34 negative human umbilical cord blood 
stem cells from the human umbilical cord blood: 
Previous studies in the laboratory have shown effective isolation of CD34 negative non-
hematopoietic stem cell population from human umbilical cord blood. The Human UCB 
which was obtained from the Fairview-Riverside University Hospital was processed 
within 4hrs after harvesting. It was diluted in PBS and supplemented with bovine serum 
albumin (BSA). The human UCB was then subjected to Ficoll-Hypaque density gradient 
centrifugation in order to separate the mononuclear cell (MNCs) population. These 
mononuclear cells were plated in T-25 flasks at a density of about 1 million cells in a 
flask and were cultured in Dulbecco’s modified Eagle medium with Nutrient Mixture F-
12, fetal bovine serum, growth factors like bFGF and hEGF. Antibiotics like Penicillin 
and streptomycin were also added to the culture media. When cells reached 60% 
confluency, they were split in the ratio 1:3 and were maintained under the same culture 
conditions. 
Animals and MCAO surgery 
Small animal models like rats are the most widely used animal models for stroke. The 
advantage of using rats is that they are relatively inexpensive to purchase and house in 
comparison to other small animals models 
[50]
. The rat models used in the study are an 
average weight of about 300 grams. The permanent MCAO was performed in the SHR 
rats which were anesthetized with halothane and the transient MCAO was performed in 
Adult Sprague Dawley rats anesthetized with ketamine and xylazine intraperitoneally. A 
4-0 silicon coated surgical thread was inserted through the internal caratoid to the origin 
of the middle cerebral artery.  The thread that was inserted was left in place undisturbed 
for 1 hour.  
           The modified Neurological Severity Score (mNSS) was performed 24 hours after 
MCAO in order to assess the neurological impairment due to the induced stroke. 
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Infusion of nh-UCBCs 
After the induction of stroke by MCAO, the behavior of the rats was assessed in 
accordance to the neurological severity score (NSS). Following this, a cell suspension of 
human nh-UCBCs with a final concentration of 2*10
6
 cell/ml in sterile saline was 
injected into the saphenous vein. Animals were maintained on daily cyclosporine A 
administration (10mg/kg). 
TYPES OF STROKE MODELs: IN ACCORDANCE TO TIME 
POINT OF TREATMENT 
Acute Stroke Model:  
a)  
       Day o       Day1         Day 2               Day 7                     Day 14    Day 28         
 
Stroke induced     NSS test 1       Treatment                        NSS test 2                    NSS test 3            NSS test 4             
into SD rats                              Group1: nh-UCBCs were  
                                              injected intravenously. 
                                              Group2: Received either  
                                                   RN33b neural stem cells or saline.  
b) 
       Day o    Day1         Day 2        Week1   Week2               Week4           
 
Stroke induced                Treatment                                                    BDA treatment       rats killed for  
  into SD  rats                 Group1 nh-UCBCs were                                                               histology studies 
                                         injected intravenously.                                                                                  
                                        Group2: Received either  
                                         RN33b neural stem cells or saline 
 
                                        
Figure 8: Timeline for treatment with nh-UCBSc, behavior testing by mNSS and BDA 
treatment in an acute model for stroke. A) In an acute model of stroke, the stroke was induced 
at Day 0 and nh-UCBS cells were administered at Day 2 post-injury. Behavior testing in acute 
model of stoke based on modified neurological severity score (mNSS) were done on Day 0 after 
the induction with stroke and day7, day 14 and day 28 following the treatment with nh-UCBSc. 
B) BDA was administered 2 weeks post treatment with nh-UCBSc and the rats are sacrificed for 
histology studies after 2weeks following BDA treatment (week 4 after treatment). 
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        In the acute stroke model, the nh-UCBCs, saline or RN33b neural were administered 
intravenously 48 hours after the induction of injury by MCAO. In order to study the 
functional behavior of the animal, functional tests based on modified neurological 
severity score (mNSS) was conducted on week1, week2 and week 3 after stroke 
induction.  And for histological analysis of the brain tissues after treatment with the nh-
UBSCs, the stroke was induced in the animal models at day 2, following which BDA was 
administered at day 14. These animal models were then sacrificed at day 28 and the 
brains were sectioned. 
Chronic Stroke Model:  
a) 
                                                      Time points at which mNSS test was conducted after treatment 
        Day 0         3 months (3m)    3m + 2days    3m+w1       3m+w2          3m+w4         3m+w8 
        
   Stroke induced into    Treatment   
    SD rats                     with nh-UCBSCs or saline 
 
 
b)                                                                                   Time points after treatment 
          Day 0 3 month’s     3m + week 2                   3m + week 4             
 
       
       Stroke induced into       Treatment               BDA treatment               Sacrifice the rat for   
         SD rats                       with nh-UCBSCs                                                  histology studies 
 or saline 
Figure 9: Timeline for treatment with nh-UCBCs, behavior testing by mNSS and BDA 
treatment in a chronic model for stroke. A) In a chronic model of stroke, the stroke was 
induced at Day0 and nh-UCBS cells are administered after 3 months post-injury. Behavior testing 
in a chronic model of stoke based on modified neurological severity score (mNSS) were done on 
Day 0 after the induction with stroke and Day 2, Day 7, Day 14 and Day 28 following the 
treatment with nh-UCBCs. B) BDA was administered 2 weeks post treatment with nh-UCBCs 
(3m+ week2) and the rats were sacrificed for histology studies after 2weeks following BDA 
treatment (3m+week4). 
Group 1: SD rats injected with saline, (n=3) 
Group 2: SD rats injected with nh-UBSCs (75000 Cells per point), (n=4) 
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In the chronic stroke model, the nh-UCBCs or saline was administered into Sprague 
Dawley or SHR rats at 3 months after the induction of injury by MCAO. The 
neurological severity score was used in order to track the changes in the behavior of these 
animal models at day 2, week 1, week 2, week 4 and week 8 Post- treatment.  To study 
the histology of the brain tissue in a chronic model of stroke, BDA was administered 2 
weeks after nh-UCBCs treatment. The animals were sacrificed 2 weeks following the 
BDA administration and the brains were sectioned and preserved. 
 
Cell culture of non-hematopoietic CD34 negative Human umbilical cord 
blood stem cells (nh-UCBCs): 
The non-hematopoietic CD34 negative Human umbilical cord blood stem cells (nh-
UCBCs) were cultured on fibronectin coated plastic tissue culture plates (Sarstedt, 
100*20mm) at a density of about 100, 00 cells per petriplate. The cells were provided 
with UCB media which consisted of 60% Dulbecco’s modified Eagle medium: F12 
(DMEM: F12 [low glucose] (Invitrogen) and 30% MCDB 201 medium (Sigma) 
supplemented with Fetal bovine serum (Becton/ Dickinson or Invitrogen), 100 unit/ml 
Primosin (Invitrogen), 100uM L-ascorbic acid-2-PO4 (vitamin c) (Sigma), 20nM 
Dexamethasone (DXM) (Sigma), 1x insulin transferring selenium (ITS) media 
supplement (Sigma), 1mg/ml Linoleic Acid/ BSA (Sigma), growth factors like 10ng/ml 
of Recombinant human epidermal growth factor EGF (Sigma) and 10ng/ml Recombinant 
human PDGF-BB (R & D systems). The nh-UCBCs were grown until they became 80 – 
90 % confluent and formed a uniform adherent monolayer of cells. The media was 
changed every other day to make sure that the media in which the cells are grown is 
supplied with enough nutrients required for efficient growth. The nh- UCBCs were 
passaged when they were about 90% confluent by using TrypLE (Invitrogen) and 
incubating for 4 minutes at 37 °c. The TrypLE in the cell suspension was diluted by 
addition of UCB media and this cell suspension was centrifuged at 1000 rpm for 7 
minutes. The cell pellet was resuspended in UCB media and cultured on to new 
fibronectin coated plastic tissue culture plate. The split ratio for every passage is 1:3 i.e., 
cells harvested from one confluent petriplate was split to 3 petriplates in equal amounts in 
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order to maintain confluency. When the nh-UCBCs were at passage 15 and were ready to 
be passaged further, the cells were harvested using TrypLE (Invitrogen) and the 
supernatant which was obtained after centrifugation of the cell suspension was saved. 
This supernatant is the nh-UCBS cell derived condition media.  
Quantitative Real-Time Polymerase Chain Reaction Analysis: 
Total RNA was isolated and purified from the high passage P (15) nh-CD34 negative 
UCBCs and passage P (4) fibroblast cells using the RNeasy Plus Mini Kit (Qiagen, 
Valencia, CA), according to the manufacturer’s recommendations. The concentration of 
the RNA isolated was determined using a spectrophometer (Beckman DU640). The RNA 
extracted from the cells is suspended in nuclease free water (Ambiotin). For a wavelength 
of 260nm (OD) and 1cm path length, the optical density equals 1.0 for a 40µg/ml solution 
of RNA. Hence, in order to determine the concentration of RNA in the sample, the 
following calculation was performed as: 
                       Total RNA concentration = 40µg/ml x A260 reading x dilution factor. 
 The cDNA was extracted from the RNA using Sensiscript Reverse Transcriptase 
(Qiagen) which is a standard protocol for first strand cDNA synthesis using <50 ng RNA.  
 
Gene expression for the cytokines in the nh-UCBS cells: 
I. Quantitative real time polymerase chain reactions (q RT-PCR) with the CD34 negative 
nh-UCBS cells were performed using human common cytokines RT2 Profiler PCR array 
(96-well) format plate which profiles the expression of 84 important cytokine genes. This 
array includes  
a. Interferons 
b. Interleukins 
c. Bone morphogenic Proteins (bmp) 
d. Members of the TGF-B family 
e. Platelet-derived and vascular endothelial growth factors 
f. Tumor necrosis factor 
         It is used to analyze the gene expression of a focused panel of cytokines. The 
following q RT-PCR profile was used: 95°C for 10 min, 40 cycles: 95°C for 30 sec, 59°C 
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for 15 sec, 72°C for 30 sec, and 92°C for 15 sec, 55°C for 30 sec, 95°C for 30 sec and 
hold at 4°C. 
 
I. Quantitative real time polymerase chain reactions (q RT-PCR) with nh-UCBS for 
specific cytokines of interest. The primers tested were: 
 
The primers mentioned above were tagged to a Taq Man probe (Lamba, 2X Taq man 
mix) and q RT-PCR was performed with the same q RT-PCR profile as before. In order 
to ensure the specificity of q RT-PCR, melt curve analyses were performed at the end of 
all PCRs. The gene expression levels were normalized to HPRT housekeeping gene and 
then analyzed using the 2
ΔΔc
t method. 
 
Human Cytokine protein array system 
In order to check the protein expression of the different cytokines in the nh- CD34 
negative human UCBS cell conditioned media, a human protein cytokine kit (RayBiotech 
Inc.) was used.  It is cytokine protein array system used to screen the expression of 88 
human cytokines. The cytokine array membranes were placed in an 8 well tray and 2ml 
1X blocking buffer was added to both the membranes and incubated at room temperature 
for 30 minutes on a shaker. After 30 minutes, the buffer was decanted and 1ml of nh-
UCBS cell conditioned media was added to the membrane followed by overnight 
Cytokines Roles- Pro-inflammatory/ Anti-inflammatory cytokines 
IL6 Acts as both Pro and Anti-inflammatory cytokines 
IL8 Growth-regulated oncogene/cytokine-induced neutrophil chemo-attractant. 
Major mediators of inflammatory response. Pro –inflammatory cytokine 
Angiopoeitin 
1 
Important role in vascular development. Anti-inflammatory cytokine 
VEGF Promotes vasculogenesis and angiogenesis. Anti-inflammatory cytokine 
EGF Promotes growth of epidermal and epithelial tissues. Anti-inflammatory 
cytokine 
BDNF Required for the survival of cortical neurons in the brain. Anti-inflammatory 
cytokine. 
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incubation. After the incubation time, the sample was removed and washed 3 times with 
2ml of wash buffer 1 at room temperature (5minutes per wash). The membranes were 
then washed with wash buffer II 2 times with 2ml (5 minutes per wash). Primary 
antibody to be added to the membrane was prepared by diluting the Biotin Conjugated 
anti-cytokine in blocking buffer. 1ml of the diluted biotin conjugated antibodies was 
added to each membrane and incubated for 1-2 hours at room temperature. Following the 
incubation period, the membranes were washed 3X with 2ml of Wash buffer I and 2X 
with 2ml of Wash buffer II.  Secondary Antibody (1000 fold diluted HRP conjugated 
streptavidin) was prepared by adding 2µl HRP to 1998µl 1X blocking buffer. 2ml of the 
secondary antibody was added to each of the membranes and the tray was incubated at 
4°C on a shaker to ensure uniform coverage of the antibodies. The membranes were 
again washed with wash buffer I and Wash Buffer II and was ready for detection. The 
number of biological replicates for this experiment were n=3. 
 
Detection of the cytokine membrane: 
In order to detect the signal produced by the different cytokines present in the sample, 
250µl of 1X detection buffer C and 250µl of detection buffer D was added to each 
membrane and incubated at room temperature for 2 minutes. Following incubation, the 
buffer was drained and the membranes were exposed to X-ray film.  The signals were 
detected directly from membrane using the chemi-luminesence imaging system. The time 
of exposure of the membrane to the X ray film depends on the intensity of the signal in 
the membrane.  
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Interpretation of the results: 
 The levels of the cytokine expression in the nh-UCBs cells were determined by the 
intensity of immunoreactivity relative to that of the standard controls, following the 
manufacturer’s instructions. The intensities of the signal were quantified using dot blot 
analyzer built in the Image J software.  
Table 1: The 88 human cytokines tested by the human cytokine protein array system 
 
Bv2 cell culture: 
Bv2 cells were a generous gift from Dr. Ling Li (College of Pharmacy, University of 
Minnesota). BV2 is an immortalized microglia cell line. The cells were cultured in 
Dulbecco’s modified Eagle medium: F12 (DMEM: F12 [low glucose] (Invitrogen) with 
10% heat- inactivated fetal bovine serum (FBS), 100 unit/ml primosin (Invitrogen) and 
streptomycin (10µg/mL) at 37°C. Once the cells reached 80% to 90% confluency, they 
were passaged in the ratio of 1:3.The cells were plated at a density of 100, 000 cells per 
petriplate after passaging. The cells were cultured in Bv2 media for about 5-6 hours to 
ensure that the cells in culture adhered to the surface of the dish and reached 40% 
confluency. After most of the cells were observed to have attached to the surface of the 
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tissue culture plate, the existing media was removed and replaced with fresh media 
supplemented with Lipopolysaccharide [LPS] (1:10 dilution) in order to stimulate the 
activation of the microglial cells. The cells were stimulated with LPS in order to 
recapitulate the situation of the immune cells that get activated in response to the 
ischemia in-vivo. These cells were then incubated for 12 hours at 37° C. Following the 
incubation period, the media was removed and the cells in the 3 petriplates were treated 
in 3 different condition media as mentioned in table (2) and were incubated again for 12 
hours at 37 ° C. 
Table 2: Culture conditions for the BV2 microglial cells following LPS stimulation 
 
Quantitative Real-Time Polymerase Chain Reaction Analysis: Gene 
expression of the M1 and M2 microglial phenotype markers 
 
The cells cultured in the three different culture conditions were harvested using TrypLE 
(Invitrogen). In order to stop the action of the TrypLE, the saved existing condition media 
was added. The cell suspensions were centrifuged at 1000 rpm for 7minutes. The total 
RNA from the cells cultured in the different culture conditions were extracted and 
purified individually using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), according 
to the manufacturer’s recommendations.  
The cDNA was extracted from the RNA using Sensiscript Reverse Transcriptase(Qiagen) 
which is a standard protocol for first strand cDNA synthesis using <50 ng RNA. 
 
 
 
 
 
Petriplate 
Number 
Condition media Amount added 
(ml) 
Sample/Control 
1 nh-UCBS cell conditioned 
media 
10 Sample 
          2 UCB media (unconditioned 
media) 
10 Sample 
          4    BV2 media 10 Control 
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Table 3: Different M1 and M2 microglial phenotype markers that were checked for their 
expression in the BV2 cells cultured in the three different condition medias.  
 
SYBR Green quantitative real time polymerase chain reactions (qRT-PCR) were 
performed in duplicates for each primer set using Eppendorf Realplex qPCR machine. To 
ensure the specificity of PCR, melt curve analyses were performed at the end of all PCRs. 
Gene expression levels were normalized to HPRT housekeeping gene and then analyzed 
using the 2ΔΔct method. The number of biological replicates for this experiment were n 
= 3. 
 
Tissue Culture Studies 
Cell culture of mouse Neuronal stem cells (mNSCs) 
mNSCs of passage P(3) were cultured in a 6 well Ultra-Low attachment plate (Sigma 
Aldrich Inc.) covering 2 wells at a density of 0.5*10
6 
cells per well in 10× DMEM/F12 
[Dulbecco’s modified Eagle medium: F12] (Invitrogen)  with 10% L- Glutamine. These 
mNSCs were maintained in an undifferentiated state by culturing them as free floating 
3D clusters called neuropsheres. The media in which the mNSCs were cultured was 
optimized with growth factors like EGF and FGF. After the formation of neurospheres 
was visible, the neurospheres were broken down to individual cells by constant pipetting. 
This is essential as it would facilitate in counting the number of cells in culture. The 
mNSCs obtained were plated on to a 4 well chamber slide which was pre-coated with 
Poly-L-ornithine for 12 hours and further coated with laminin overnight. Approximately 
10,000 cells were plated on to each well of the 4 well-chamber slide and were exposed to 
different culture conditions (Table 4) to induce differentiation.  
 
 Microglial markers for qRT-PCR 
General microglial 
Marker 
MHC class II 
M1 Phenotype marker iNOS, CD86  
M2 Phenotype marker CD206, Arg-1, CD-163 
Housekeeping genes HPRT, β-Actinin 
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Table 4: Showing the 4 well chamber slide with the mNSCs in each chamber cultured in 
the following conditions.  
Well 1 of chamber slide: nh-UCBS cell conditioned medium 
Well 2 of chamber slide: UCB media (unconditioned media) 
Well 3 of chamber slide: Fibroblast cell conditioned medium 
Well 4 of chamber slide: NSC media  
 
IMMUNOCYTOCHEMISTRY  
The mNSCs plated which adhered to the surface of the 4 well-chamber slide were fixed 
by removing the different media from the wells and adding 700µl of 4% 
Paraformaldehyde (PFA) (Protocol) per well followed by 5-10 minutes of incubation at 
room temperature. After 10 minutes, the PFA was removed and the well was washed 
twice with PBS. Blocking buffer was prepared by adding 5% Donkey Serum (Jackson 
Immuno Research Laboratories) to PBS and filtering. Permeabilizing buffer [PBS-T] was 
prepared by adding 0.1% Tween-20 to PBS.  The PBS was removed from the cells and 
700µl of permeabilizing buffer was added to each well and incubated for 10 minutes at 
room temperature. After the incubation period, the permeabilizing buffer was removed 
and was blocked with blocking buffer (PBS + 5% Donkey serum) for 30 minutes.  The 
primary antibody and secondary antibody treatments were performed according to table 
(5). The cells were also stained with DAPI by diluting DAPI 1:1000 in PBS.  
 
Table 5: Antibodies used for immunostaining and their dilutions 
 
UCB  
SUP 
1 
UCB 
MED 
2 
FIB  
SUP 
3 
NSC 
MED 
4 
S.No. Primary 
Antibody 
Company Dilution Secondary 
Antibody 
Company Dilution 
1 Rabbit 
Anti-MAP2 
Sigma 1:1000 Alexa fluro 555 
Donkey anti- 
rabbit  IgG 
Invitrogen 1:500 
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Neurological Severity Score 
In order to determine the improvement in the behavior of the animal model affected with 
stroke before and after injection of the nh-CD34negative Human umbilical cord blood 
stem cells, the most common neurological scales known as the modified neurological 
severity scores (m NSS) was used.  The mNSS includes many tests to check for the 
function of motor (muscle status and abnormal movement), sensory (Tactile, visual and 
proprioceptive), reflex and balance tests. In our study we used behavior tests like limb 
placement test, stepping test, body swing test and adhesive removal (Table 6). 
 
Table 6: The different behavioral tests performed in the acute/ chronic stroke model 
based on the modified neurological severity score (mNSS). 
Statistics 
Statistical analyses of all the data obtained were performed by the Student t-test for 
comparison between two samples and to determine the statistical significance between 
the two groups. ANOVA one way significance test was used when there were more than 
two samples to determine statistical significance. Bolferoni-HOLM test was used to find 
the particularly significant sample, following the ANOVA test. The standard error bars in 
all the graphs represents the standard error means (SEM). 
 
 
 
Behavioral test Function 
Forelimb Placement Assesses forelimb function and placing 
deficits 
Stepping test Assesses sensorimotor function, motor 
coordination and placing deficits during 
locomotion 
Body swing test Assess asymmetrical motor dysfunctions. 
Adhesive removal test Assesses tactile responses and asymmetries 
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Results 
Cell culture of CD34 negative nh-UCBCs 
 
CD34 negative non-hematopoietic umbilical cord blood stem cells (nh-UCBCs) were 
grown in accordance to the procedure described in detail in the methods section of the 
thesis. The nh-UCBSCs have a characteristic flat, fibroblast like morphology as 
represented in figure 10. The cells in figure 10 were at passage 18; which is considered as 
high passage nh-UCBS cells.  
             No occurrences of teratomas were observed in the animal models after treatment 
with this specific nh-UCBS cell line isolated in the Department of Neurosurgery. 
 
 
 
 
 
 
 
 
 
Figure 10: Cell culture of nh-UCBCs. The non-hematopoietic human umbilical cord 
blood stem cells in culture at passage P (18). 10X light microscopic image (200µm) 
 
Gene expression analysis for the pro-inflammatory and anti-inflammatory cytokines 
present in the nh-UCBS cells.  
Previous study in the lab demonstrated that injecting CD34 negative nh-UCBS cells into 
an acute model of stroke induced by MCAO, caused 50 % reduction in the lesion volume 
which suggests that the nh-UCBS cells that are being injected are modulating the immune 
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response in the animals with ischemic brain injury. Therefore, we examined the profile of 
inflammatory genes (pro and anti-inflammatory) that are present in these cells using 
Profiler PCR array initially followed by qRT-PCR analysis of specific cytokines.  
I. Profile PCR array analysis 
The use of an array enables us to test 84 different cytokines in one experiment. The 
expression pattern of the cytokines is summarized below. 
Interleukins: The expression of anti-inflammatory cytokines like IL-10, IL-4, Il-13 and 
IL-8 were observed in the high passage nh-UCBS cells. The cytokine IL-6 acts both as a 
pro-inflammatory cytokine as well as an anti-inflammatory cytokine depending on the 
stimuli it is exposed to and the gene expression of IL-6 was low in the nh-UCBS cells.  
(Figure 11A) 
Growth factors: The gene expression of the growth factors like BMPs, CSF, FIGF, 
TNFSF, VEGFA, GDF and PDGF were seen in the nh-UCBS cells. It is unclear if their 
expression level is statistically significant due to the limitations in the experimental set-
up which allows samples to be tested only once. The expression of anit-inflammatory 
growth factors like ANGPT1 and VEGFA responsible for contributing to the brain repair 
process as observed by other research groups was seen to be expressed by the nh-UCBS 
cells.(figure 11B).  
Other chemokines: In the gene expression array, other chemokine’s like SPP1, THPO 
and FASLG were tested. Of note is the expression level of secreted phosphoprotein1 
(SPP1). SPP1 is a cytokine that upregulates the expression of the IFN-γ and IL-12 and is 
considered to be a pro-inflammatory cytokine. In the result obtained from this 
quantitative profile PCR array, SPP1 is not expressed in nh-UCBS cells (figure 11C). 
II. qRT-PCR analysis of selected cytokines 
The gene expression of selected cytokines like ANGPT1, IL-8 and VEGFA was analyzed 
using qRT-PCR in the nh-UCBS cells and fibroblast cells. These cytokines are said to 
play an important role in vasculogenesis and angiogenesis. The high expression levels of 
the cytokines were seen in the nh-UCBS cells (figure 11D). 
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A) Interleukins: 
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B) Growth Factors 
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C) Chemokines: 
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D) Gene expression for selected cytokines by qRT-PCR: 
 
 
 
 
 
 
 
 
 
Figure11: (A-C) Quantitative expression of the pro-inflammatory and anti-inflammatory 
cytokines in the nh-UCBCs (Green) by using the human common cytokines RT2 Profiler 
PCR array. a) The quantitative gene expression of various Pro and anti- inflammatory 
interleukins in the nh-UCBCs. b) The quantitative gene expression of growth factors in nh-
UCBCs c) The quantitative gene expression of chemokines in nh-UCBCs.  
Figure (D): The quantitative gene expression of a selective pro-inflammatory and anti-
inflammatory cytokines like ANGPT1, IL-8 and VEGFA in the nh-UCBCs (Green) by q RT-PCR 
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Protein expression for the Pro-inflammatory and Anti-inflammatory cytokines 
present in the nh-UCBS cell conditioned media and Fibroblast cell conditioned 
media. 
There is increasing evidence that the therapeutic effect of the mesenchymal stem cells 
(MSCs) isolated from the human umbilical cord blood (human UCB) helps in 
ameliorating the behavioral deficits induced in a stroke model due to its ability to produce 
cytokines and other factors that are responsible for the regulation of inflammation, 
angiogenesis, and also promotion of cellular growth 
[49]
. In order to determine if the nh-
UCBCs also secrete such factors that could influence the tissue environment and aid in 
tissue repair without directly contributing through cell engraftment or differentiation into 
other cell types, we checked the protein expression of the various cytokines (Interleukins, 
growth factors, chemokine’s and MMP-inhibitors) present in the nh-UCBS cell 
conditioned media. We used a human cytokine protein array to test the composition of 
the media conditioned with nh-UCBCs. Cytokine arrays were used to determine the 
expression levels of 88 different cytokines (table 1) in the sample (Figure 12A). The 
cytokine analysis using this protein array system was done as biological replicates (n=3). 
In the membrane each dot represents a particular cytokine as mentioned in the materials 
and methods section of this thesis. The intensity of each cytokine was analyzed using dot 
blot analysis in image J software.  The intensity of the cytokine was calculated with 
reference to the average intensity of the positive controls for each membrane. The 
negative controls are of 0% intensity in all of the membranes. The cytokine expression 
levels between the nh-UCBS cell conditioned media were plotted as the mean values of 
the intensities from all three biological replicate derived membranes. The cytokines were 
grouped in accordance to their sub-type. Here Figure 12b, c, d, and e represents the 
expression of interleukins, growth factors, chemokine’s and MMP-inhibitors respectively 
in the sample tested. Increased expression of the growth factors like VEGF and MCSF. 
ANGPT1 is known to contribute to angiogenesis was observed in the nh-UCBS cell 
derived conditioned media. Moreover, protein expression of the anti-inflammatory 
cytokines like IL-4 and IL-10 was also seen in the sample tested.  The protein expression 
of osteoportin cytokine was also high in the nh-UCBS cell condition media. Osteoportin 
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has chemotactic properties which can contribute to cell recruitment to inflammatory sites. 
It functions as a adhesion protein involved in cell attachment and wound healing. 
A) nh-UCBS cell conditioned media incubated membrane                            
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C) Growth factors: 
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D) Chemokines: 
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E) MMP inhibitors  
 
 
 
 
 
 
 
 
Figure 12: Protein expression of the pro-inflammatory and anti-inflammatory cytokines 
present in nh-UCBS cell conditioned media (Green) by Human Cytokine protein array 
system.  
(A) Represents the cytokine membrane incubated with nh-UCBS cell conditioned media. The 
brighter the dot in the membrane, stronger is the intensity of the signal produced by the particular 
cytokine.  
(B) Protein expression of the pro-inflammatory and anti-inflammatory interleukins present in the 
nh-UCBS cell conditioned media.  
(C) Protein expression of the pro-inflammatory and anti-inflammatory growth factors present in 
the nh-UCBS cell conditioned media.  
(D) Protein expression of the pro-inflammatory and anti-inflammatory chemokine’s present in the 
nh-UCBS cell conditioned media.  
(E) Protein expression of the MMP- inhibitors present in the nh-UCBS cell conditioned media. 
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M1 and M2 microglial phenotype  
In order to examine if the nh-UCBS cells exert tissue protective benefits, by reducing the 
inflammatory microglial behavior, we co-cultured the BV2 cell (microglial cells) in nh-
UCBS cell conditioned media. BV2 cells co-cultured in UCB media and BV2 media were 
used as controls in this experiment. There are two distinct phenotypes of microglial cells, 
viz.  M1 phenotype (classical, induced by LPS/ IFN-γ) and M2 phenotype (alternative, 
induced by IL-4 or IL-13) 
[54]
. The BV2 cells acquire classical activation pattern (M1) 
when activated with LPS.  M1 phenotype microglia is pro-inflammatory hence promotes 
inflammatory response in-vitro when the BV2 cells are stimulated with LPS. The M2 
phenotype microglia is anti-inflammatory and is responsible for secreting cytokines that 
help in wound healing and tissue repair after injury 
[53]
. Hence in order to examine if the 
nh-UCBS cell conditioned media helps in modulating the immune response by the 
activation of the M2 phenotype, the BV2 cells in culture following the stimulation by 
LPS was treated with nh-UCBS cell conditioned media. The expression of M1 markers 
(iNOS, CD-86) and M2 markers (ARG-1 and CD-206) was analyzed in the cells obtained 
after the co-culturing of the BV2 cells in the three different culture conditions (figure 13). 
It was observed that Arg-1 which is a M2 phenotype marker was expressed higher in the 
BV2 cells co-cultured with nh-UCBS cell conditioned media when compared to the BV2 
cells cultured in BV2 media (figure 13B). But the expression of Arg-1 in the BV2 cells 
cultured in the UCB media (unconditioned media) was similar to its expression in the 
cells cultured with nh-UCBS cell conditioned media (figure 13B). The expression of 
iNOS, a M1 phenotype marker was expressed significantly higher in the BV2 cells 
cultured in nh-UCBS cell condition media compared to the cells cultured in BV2 media 
(figure 13A), which is contrary to our hypothesis. 
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A)   
 
 
 
 
 
 
 
 
 
B)  
 
 
 
 
 
 
Figure 13: Quantitative assessment of M1 (iNOS and CD-86) and M2 (Arg-1 and CD-206) 
microglial phenotype marker expression in the BV2 cells cultured in 3 different culture 
conditions: nh-UCBS cell conditioned media (Green), UCB media (unconditioned media) 
(Red) and BV2 media (Blue) by qRT-PCR        
A) The quantitative expression of the M1 markers: iNOS and CD-86 in the cells cultured in the 3 
different culture conditions by qRT-PCR. 
B) The quantitative expression of the M2 marker: Arg1 and CD-206 in the cells cultured in 3 
different culture conditions by qRT-PCR.  
[Number of biological replicates=3. Asterisks denote statistical significance (atleast P<0.05; 
ANNOVA one way significance test and Bolferoni HOLM test)] 
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Trophic effects of nh-UCBSC on neural stem cells 
In this experiment, we examined whether the neural stem cells grown in nh-UCBS cell 
conditioned media has the ability to differentiate into neurons with longer dendrites in 
comparison to the mNSCs grown in other culture conditions like UCB media 
(unconditioned media), fibroblast cell conditioned media and neural stem cell (NSC) 
media. It was observed that the mNSCs cultured in nh-UCBS cell conditioned media 
formed a greater number of colonies of neural stem cells, in comparison to the mNSCs 
cultured in the other condition media (data not shown).  Moreover the size of each colony 
was bigger when mNSCs were cultured in nh-UCBS cell conditioned media (figure 14D). 
This indicates that the nh-UCBS cells are secreting certain growth factors that are helping 
in this robust proliferation of neuronal stem cells. The number of colonies formed by the 
mNSCs cultured in fibroblast condition media was greater than the number of colonies 
formed in UCB media, but less than the number of colonies formed in nh-UCBS cell 
conditioned media. Though it was not possible to visualize the increase in the length of 
the dendrites when the NSCs were cultured in the nh-UCBS cell conditioned media, the 
significant increase in the number of colonies and increased size of each colony when the 
mNSCs were cultured in nh-UCBS cell conditioned media compared to other culture 
conditions, shows that these nh-UCBS cells are responsible for secreting certain factors 
that contribute to neuroplasticity 
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D) 
 
Figure 14: Immunocytochemistry of the m NSC in the 3 different culture conditions in the 4 
well chamber slide 
 (A) (i) Phase contrast image of the mNSCs cultured in Neural stem media (ii) Staining for the 
mNSCs in NSC media. Merged image of DAPI (blue) and GFP-positive neural stem cells 
(GREEN).  
(B) (i) Phase contrast image of the mNSCs cultured in UCB media (unconditioned media) (ii) 
Staining for the mNSCs in UCB media. Merged image of DAPI (blue) and GFP-positive neural 
stem cells (GREEN). Apoptosis of mNSCs was observed when cultured in UCB media. The 
numbers of GFP positive mNSCs were very few. The number of colonies formed was very scanty 
with not many cells in every colony. Hence the size of the colony was very small. 
(C) (i) Phase contrast image of the mNSCs cultured in fibroblast cell conditioned media (ii) 
Staining for the mNSCs in fibroblast cell conditioned media. Merged image of DAPI (blue) and 
GFP-positive neural stem cells (GREEN). The morphology of the neural stem cells mNSC seems 
changed.  
(D) (i) Phase contrast image of the mNSCs cultured in nh-UCBS cell conditioned media (ii) 
Staining for the mNSCs in nh-UCBS cell conditioned media. Merged image of DAPI (blue) and 
GFP-positive neural stem cells (GREEN). The neuronal stem cells cultured in the nh-UCBS cell 
conditioned media formed many colonies (n=20). The size of every colony was larger when 
compared to the colonies in other culture conditions i.e. there were more number of cells forming 
a colony when mNSCs were cultured in nh-UCBS cell conditioned media.  
[Arrows indicate colony formation by mNSC in B, C and D] 
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DISCUSSION 
It is known from previous work in the laboratory that a novel population of CD34 
negative non-hematopoietic stem cells can be isolated from the human umbilical cord 
blood. Those cells when injected systemically into a rat 48 hours after the induction by 
stroke or direct injection of these stem cells into the brain parenchyma at 3 months after 
ischemic stroke, helped in the alleviation of the stroke induced deficits, improving the 
behavior of the animal model seen by performing various functional tests. The human 
cells injected into the animal model were not present in the brain 2-3 days after 
administration, hence it was hypothesized that the recovery process in the animal model 
is mediated by a mechanism other than cell-replacement. The focus of this thesis was to 
explore the other mechanism(s) of action that was responsible for the improved recovery 
in animal model induced with stroke. 
         Ischemic brain stroke triggers the complicated inflammatory cascade in the brain 
that eventually causes pronounced cell death adjacent to the obstructed vasculature. In the 
first part of this study we postulated that the nh-UCBS cells that are injected into the 
stroke induced animal model helps in preventing the apoptotic cascade and also 
modulates the inflammatory response to the ischemic injury thereby improving the 
functional behavior of the animal. Hence the initial focus of the study was to analyze the 
expression level of the various pro- and anti-inflammatory cytokines in the non – 
hematopoietic umbilical cord blood stem cells. This was done using a quantitative RT2 
PCR profile array in which the 96 well plate had a variety of built in primers for the 
cytokines of interest. We observed that the gene expression level of the variety of 
interleukins, growth factors, MMP inhibitors and other chemokine’s was in the nh-UCBS 
cells. Of specific interest, high expression of growth factors like ANGPT1 and VEGF 
responsible for angiogenesis and vasculogenesis was observed in the nh-UCBS cells. 
This preliminary observation needs to be repeated with more replicates to generate 
significant results. Another interesting observation was the expression of the chemokine 
secreted phosphor protein1 (SPP1) which is a pro-inflammatory cytokine that promotes 
the migration of inflammatory cells to the wound site and also acts an adhesive protein to 
retain the cells at the site. SPP1 was not seen to be expressed in the nh-UCBS cells. 
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Further studies need to be performed to understand the significance of this observation. 
Next, in order to confirm the gene expression level of the cytokines, we checked the 
secretion of the pro-inflammatory and anti-inflammatory level of cytokines in the nh-
UCBS cell conditioned media. Protein level of a variety of interleukins, growth factors, 
chemokine’s and MMP inhibitors were observed in the nh-UCBS cell conditioned media, 
The protein expression of ANGPT1 was significantly high in the nh-UCBS cell 
conditioned media, which correlated with the gene expression of the ANGPT1 cytokine 
in the nh-UCBS cells.  
           We next hypothesized that nh-UCBS cells can modulate the neuroinflammatory 
immune response by activating microglial cells. To test this hypothesis, we studied the 
influence of the nh-UCBS cell conditioned media on the BV2 microglial cell line. 
Microglial BV2 cells were co-cultured with the nh-UCBS cell conditioned media after 
the stimulation of the BV2 cells by LPS. The LPS is responsible for activating the 
inflammatory response from these immune cells in an in-vitro environment. We 
postulated that the nh-UCBS cell conditioned media will help in the transition of the M1 
phenotype of macrophage to the M2 phenotype which is the responsible phenotype for 
wound healing and tissue repair. Though in our observations, we noticed that the nh-
UCBS cell conditioned media did not significantly reduce the gene expression of the M1 
phenotype macrophages, as seen by the expression of the M1 markers (iNOS and CD-86) 
in the Bv2 cells cultured in three different culture conditions, we did observe a significant 
increase in the expression of M2 marker (Arg-1) in the BV2 cells co-cultured in the nh-
UCBS cell conditioned media compared to the BV2 cell condition media which states 
that the nh-UCBS cells are activating the transition from the M1 to M2 phenotype. 
However, the unconditioned culture media used to grow nh-UCBS cells also had a 
positive effect on the generation of the M2 phenotype which is a confounding factor in 
this interpretation. 
                       The second part of the study was to understand the mechanism of non-
neural stem cell based approach for mediating recovery from stroke which is 
neuroplasticity. We expected to see the increase in the dendritic length of the neurons 
cultured in the nh-UCBS cell conditioned media compared to the neuronal stem cells 
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cultured in other control culture condition media. But we observed that the nh-UCBS cell 
condition media helped in the increase of the number and size of the colonies formed by 
neural stem cells. We believe that this might be due to the various growth factors secreted 
by the nh-UCBS cells that help in the robust proliferation of the nh-UCBS cells. But the 
exact growth factor which is responsible for this is yet to be known.  
            Overall we had expected to see the expression of anti-inflammatory cytokine like 
IL-10 to be high in the nh-UCBS cell and in the nh-UCBS cell conditioned media. It is 
known that treatments that enhance IL-10 expression around the infarct site, reduces the 
infarct volume 
[48] [52]
 and similar observation of reduced infarct size was noticed after 
treatment with nh-UCBS cells in a rat model of stroke. Cytokine like IL-10 also may 
directly bind to NF-kB, the key transcriptional regulator of genes thereby inhibiting its 
activity and thereby modulating the release of the pro-inflammatory cytokines such as 
TNF-α and IL-1β in the stroke induced model. We observed that the gene expression of 
the most studied anti-inflammatory cytokines like IL-4 and IL-10 with regard to 
contributing to the recovery process after ischemic brain injury was high in the nh-UCBS 
cells We also believe that the nh-UCBS cells release a number of neuroprotective growth 
factors that is responsible for the mechanism of neuroplasticity and neurorepair which 
ultimately improves the neurobehavior of the animal model induced with stroke. 
        It is however unclear whether the nh-UCBS cells that are injected into the animal 
model is reducing the inflammation by releasing cytokines that help in lessening cell 
death within the infarcted region, if its due to the activation of the macrophage cells in 
the brain and peripheral organs of the body which changes from M1 to M2 phenotype 
thus helping in the clearance of cellular debris or whether it is a combination of the two 
events. But it is certain that the nh-UCBS cell treatment alters the cellular and molecular 
program initiated by cerebral ischemia. 
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